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Abstract A questionnaire (Migraine Questionnaire; MQ)
was developed to help pharmacists identify consumers
with migraine suitable for non-prescription treatment with
a triptan. Adults, who knew or thought that they had
migraine, participated in three, sequential, community-
based studies to validate the MQ. Overall, 1,353 subjects
completed independent assessments with a pharmacist and
a clinician (reference standard). The accuracy of the phar-
macist assessment of suitability for a triptan was compared
with the clinician assessment. Clinicians using their stan-
dard practice determined that triptan therapy was suitable in
76.8% of cases compared with 48.8% for pharmacists using
the MQ. The lack of concordance between pharmacists and
clinicians in the false-positive cases (n = 113 of 660 sub-
jects considered suitable for triptan by the pharmacists)
usually related to headache diagnosis (57.5%), not safety
aspects. The MQ is an effective tool for pharmacists to
guide appropriate recommendation of a non-prescription
triptan for migraine.
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Introduction
According to the WHO, headache should be considered as
a public health concern as many people troubled by
headache do not receive effective care [1]. Migraine is one
of the most common types of headache and is characterised
by recurrent episodes of pain with associated symptoms
that frequently result in disability. A survey conducted
across several countries showed that migraine affects
approximately 9% of the general population [2]. Although
most attacks were classified as fairly severe to very severe,
many of those affected by migraine do not consult a doctor
and rely on over-the-counter (OTC) medications for
symptom relief [2]. The prevalence of migraine is highest
among those aged between 25 and 55, the years of life
when work productivity is highest [3]. Migraine poses a
significant burden on individuals and on society as a result
of its high prevalence and associated disability [3, 4].
Reducing the burden of migraine and closing the gap
between treatment opportunities and actual practice has
been recognised as a public health priority [4].
The triptans are effective and well-tolerated treatments
for migraine [5]. Sumatriptan, the first triptan to be mar-
keted, has been available as a prescription medicine for
17 years. However, relatively few people who consult a
physician about migraine are prescribed a triptan (3–19%)
[2]. In an effort to broaden community access to these
effective treatments, sumatriptan 50 mg and naratriptan
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2.5 mg tablets were launched in 2006 for use as non-pre-
scription medicines (available from pharmacies) in the
UK and Germany, respectively. Wider access to these
treatments as result of their reclassification (termed re-
scheduling in Australia) may result in improved treatment
of migraine and reduce migraine-related disability [6], thus
helping to address this public health priority [4].
To maintain the positive benefit–risk balance of a triptan
with non-prescription availability, the product information
was strengthened and a pharmacy questionnaire, hereafter
called the Migraine Questionnaire (MQ), was developed
for use by the pharmacist to guide appropriate recom-
mendation at the point of sale.
The MQ was tested sequentially in the UK, Australia
and Germany, where applications to reclassify sumatriptan
(UK and Australia) or naratriptan (Germany) for non-pre-
scription use were later submitted to the relevant regulatory
agency. The design of all three studies was similar. Sub-
jects completed two independent assessments with
appointed healthcare professionals (HCPs), a pharmacist
and a clinician. The aim in each study was to determine the
accuracy of the pharmacist assessment of suitability for
treatment with a triptan compared with the primary care
clinician assessment.
The first version of the MQ was based on the proposed
product information for non-prescription sumatriptan. It
included a three-item migraine screening tool that had been
developed and validated for use in primary care [7], and an
item on headache frequency adapted from a diagnostic
screening questionnaire [8]. The MQ was revised in
accordance with the findings from each study. Advice from
independent experts in neurology, cardiology, general
practice and pharmacy practice and results from a user
testing study with consumers and pharmacists were also
taken into account in developing the MQ.
Methods
Study design
All three studies were multi-centred and community-based.
Adults C 18 years were recruited through advertisements
(print and radio) local to the study sites. Individuals who
wanted to participate in the studies contacted a call centre,
and appointments were arranged. Each subject completed
two assessments with appointed independent HCPs. No
treatment was provided in any of these studies.
All pharmacists were trained prior to taking part in the
studies. The pharmacists were provided with information
and a training manual on migraine and its treatment and
on the use of the MQ. The MQ contained guidance notes
to assist the pharmacist during the assessments (see
Appendix). Minor differences between the product infor-
mation for sumatriptan and naratriptan were reflected in the
text of the MQ tested in Germany (naratriptan). Training
for the clinicians was less intensive. A copy of the pre-
scribing information (product information in Australia) for
the prescription product was provided.
The first assessment took place in a community phar-
macy. The pharmacist used the MQ to assess whether the
subject had migraine and was potentially suitable for non-
prescription treatment with sumatriptan (UK and Australia)
or naratriptan (Germany). The pharmacist was not required
to make a formal diagnosis of migraine although a subject
was considered to have migraine if certain responses were
provided to those items in the MQ that concerned migraine
history.
The second assessment occurred within 2 weeks. The
subject was assessed for migraine and suitability for
sumatriptan (or naratriptan) by a primary care clinician
using his or her standard clinical practice. The clinician’s
assessment was the reference standard. The clinicians had
no prior clinical knowledge about the subjects other than
that they were aged C 18 years and knew or thought they
suffered from migraine.
Each study was conducted in accordance with the
principles of the Declaration of Helsinki (1996). Ethics
approval was obtained from: RSSL Independent Ethics
Committee, Reading (UK); the National Research and
Evaluation Ethics Committee of the Royal Australian
College of General Practitioners (Australia), and the Ethics
Commissions for the (1) University of Duisburg-Essen, (2)
North Rhine and (3) Westfalen-Lippe. All subjects pro-
vided written, informed consent.
Statistics
A pilot study was conducted in the UK with a shortened
version of the MQ. The results from this study (not shown)
were used in the sample size calculation for the three
validation studies described herein.
The primary endpoint was the false-positive rate, one of
the measures of the accuracy of the pharmacist assessment
of subject suitability. A false-positive was defined as a
subject considered suitable for sumatriptan or naratriptan
by the pharmacist, but not by the clinician. The false-
positive rate is the total number of false-positives expres-
sed as a proportion of the total number of subjects
considered suitable by the pharmacists. Other measures of
accuracy included specificity, positive predictive value,
sensitivity, and negative predictive value. The proportions
of interest were estimated with 95% confidence intervals
(CIs). For calculation of the 95% CIs, either the normal
approximation or the exact method was used as appropri-
ate. No hypotheses were tested.




It was planned to recruit 450 subjects for the UK study; the
recruitment target was 465 in the other two studies. Actual
numbers of subjects recruited and those who completed
both assessments are shown in Table 1 together with the
number of participating HCPs. The number of clinicians
was increased in the Australian and German studies to
reduce the number of assessments per clinician.
Demographics
Across the three studies, most subjects who completed both
assessments were female (79–83%) and Caucasian (91–
99%), and the mean age ranged from 36 to 42 years.
Migraine diagnosis by the clinicians
The proportion of subjects diagnosed with migraine by the
clinicians was similar across the studies ranging from 84.2
to 88.9%. However, the diagnosis rate varied between the
individual clinicians. For the five clinicians in the UK
study, this ranged from 68.5 to 100%, each of whom
assessed between 55 and 110 subjects. There were also
marked differences between clinicians in the distribution of
the specific headache diagnoses: of 31 subjects diagnosed
with chronic daily headache in the UK study, one clinician
identified 87% of these cases, and of 20 subjects diagnosed
with tension-type headache, one other clinician identified
50% of these cases.
Assessment of suitability for treatment with a triptan
A summary of the accuracy of the pharmacist assessment of
suitability for a triptan based on subjects who completed
both assessments is shown in Table 2. In all three studies,
pharmacists were more cautious than clinicians in assessing
suitability. The overall proportion of subjects determined to
be suitable for a non-prescription triptan (660/1,353;
48.8%) was lower than that for a prescription triptan (1,039/
1,353; 76.8%).
Accuracy of the pharmacist assessment of suitability
Individual measures of the accuracy of the pharmacist
assessment of suitability are shown in Table 3. The false-
positive rate was 17.1% (113/660) overall, and 20, 16.7 and
15.5% in the UK, Australian and German studies,
respectively.
Sensitivity and specificity were relatively low (Table 3).
This is not surprising given that the pharmacists and the
clinicians were assessing suitability in accordance with the
labelling for non-prescription and prescription triptans,
respectively.
The false-positive cases (n = 113) are of interest as
these could flag potential safety concerns regarding the
pharmacist recommendation. Accordingly, the reason(s) as
to why the clinicians classified these subjects as unsuitable
for a triptan were reviewed. The reasons were categorised
into two groups as shown below.
False-positive cases: subjects who did not have migraine
Overall, 57.5% of false-positive subjects (65/113) had been
diagnosed with a headache other than migraine by the
clinicians (Table 4). Chronic daily headache was the most
common diagnosis (54.5%), reflecting the high prevalence
of this diagnosis in the UK study. Tension-type headache
was the most frequent diagnosis for false-positives made by
clinicians in the Australian (64.7%) and German (84.6%)
studies.
Out of the 65 false-positive subjects with a diagnosis
other than migraine, 56.9% (range 41.2–72.3% across the
studies), had previously been diagnosed with migraine and/
or prescribed medication to treat migraine by their doctor,
and 89.2% (range 77.3–94.1%) gave a positive response to




Pharmacists 25 18 27
Clinicians 5 11 11
Total number of subjects recruited 462 471 470
Subjects who completed assessments
with both HCPs
439 456 458














Yes No Total Yes No Total Yes No Total
Pharmacist
Yes 156 39 195 130 26 156 261 48 309
No 161 83 244 221 79 300 110 39 149
Total 317 122 439 351 105 456 371 87 458
a Sumatriptan 50 mg for the studies in the UK and Australia; nara-
triptan 2.5 mg in Germany
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at least two out of the three items in the migraine screening
tool [7] that formed part of the MQ.
False-positive cases: subjects with migraine but whose
general medical history was incompatible with triptan
treatment
Overall, 42.5% of the false-positive subjects (48/113) were
diagnosed with migraine by the clinicians but deemed
unsuitable for a triptan for other reasons (Table 5). In some
cases, the pharmacist appeared to have missed contraindica-
tions for non-prescription supply of triptan, e.g. hypertension
(n = 2), previous bad reaction/allergy to triptan (n = 3) and
rare variant migraine (n = 2; both cases were identified by the
same clinician). Several other reasons provided were con-
sidered clinically unimportant, e.g. migraine managed well
with current over-the-counter (OTC) treatments.
Table 3 Analysis of the pharmacist assessment of suitability
Measure UK studya (n = 439) Australian studya (n = 456) German studya (n = 458)
Value 95% CI Value 95% CI Value 95% CI
False-positive rate 39/195 = 0.200 0.144, 0.256 26/156 = 0.167 0.108, 0.225 48/309 = 0.155 0.115, 0.196
Specificity 83/122 = 0.680 0.598, 0.763 79/105 = 0.752 0.670, 0.835 39/87 = 0.448 0.344, 0.553
Positive predictive value 156/195 = 0.800 0.744, 0.856 130/156 = 0.833 0.775, 0.892 261/309 = 0.845 0.804, 0.885
Sensitivity 156/317 = 0.492 0.437, 0.547 130/351 = 0.370 0.320, 0.421 261/371 = 0.704 0.657, 0.750
Negative predictive value 83/244 = 0.340 0.281, 0.400 79/300 = 0.263 0.213, 0.313 39/149 = 0.262 0.191, 0.332
a Sumatriptan 50 mg for the studies in the UK and Australia; naratriptan 2.5 mg in Germany
Table 4 Clinician-reported headache diagnosis in false-positive
subjects who did not have migraine










Tension-type headache 7 11 22
Cluster headache 1 – –
Cervicogenic headache – – 3
Other 1b 3c 1d
Missing 1 – –
Total 22 17 26
a Two diagnoses of non-migraine headache were given to one subject
b ‘‘Multiple headaches and probably did have migraine in the past.
Now many headaches not migraine’’
c Headaches associated with hypoglycaemia (n = 1); no headache
(n = 1); no symptoms of migraine (n = 1)
d Atypical facial neuralgia
Table 5 Clinician-reported reasons why false-positive subjects with
migraine were unsuitable for a triptan
Clinician reason why subject








Vomits early in migraine
attack/needs non-tablet
medication due to vomiting
or requiring very swift
onset of action
4 1 3
Duration of headache too short 3 – –
Migraine managed well with
current OTC treatments
3 – 11c
Aura only 2 –







Migraine not suitable for
sumatriptan/naratriptan
– 2e 2f
Previous bad reaction or allergy
to sumatriptan/naratriptan
1 1 1
Other 1g 1h –
Total 17 9 22
a Where a clinician identified multiple reasons for unsuitability, the
first medically significant reason is listed
b Sumatriptan 50 mg for the studies in the UK and Australia; nara-
triptan 2.5 mg in Germany
c All 11 cases identified by one clinician
d Uncontrolled hypertension (n = 2)
e Hemiplegic migraine (n = 2); both cases identified by one clinician
f Clinician reported—‘‘Post-traumatic stress disorder, coordination
barely possible, memory impaired, alternative therapies’’ in one case.
No further information from the clinician for the second case
g Female, 27.5 years, with cardiac pacemaker. No personal or family
history of heart disease according to MQ responses collected by
pharmacist
h Taking antipsychotic medication (n = 1)
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Contraindications related to cardiovascular disease
and cardiac risk factors
Use of a triptan in individuals with a history of, or at high
risk of, cardiovascular disease is an important safety con-
sideration. The pharmacists identified 100 subjects with one
or more contraindications relating to cardiovascular disease
(Table 6). These contraindications apply to sumatriptan and
to naratriptan, irrespective of prescription or non-prescrip-
tion status. Most of these subjects (86.0%) were classed as
unsuitable for treatment with a triptan by the pharmacist.
The clinicians may have placed less weight on this aspect of
medical history in assessing the overall benefit-risk for
individual subjects as only 32.0% of these subjects were
reported to be unsuitable for treatment with a triptan.
The MQ reflects the requirements of the product infor-
mation for non-prescription sumatriptan and naratripan as
subjects with three or more cardiac risk factors (see
Table 6 footnote) are considered unsuitable for a triptan.
Labelling for the prescription products is less rigid and
enables clinicians to use clinical judgement in assessing
this aspect. In almost all cases, the pharmacists concluded
that subjects with three or more risk factors were not
suitable for a non-prescription triptan (Table 6). Overall,
94.9% of subjects with at least three risk factors were
considered to be unsuitable for a triptan by the pharmacists,
whereas the clinicians reported that only 28.8% of these
subjects were unsuitable for a triptan.
Suitability rates for pharmacy supply of a triptan
The lowest pharmacist suitability rate was found in the
Australian study (34.2%; Table 2). Two questions were
identified as being more restrictive than had been intended.
The pharmacists were provided with guidance notes to aid
interpretation of responses to the MQ (see Appendix). The
guidance notes for the MQ in the Australian study stated that
those subjects whose migraine headaches lasted [24 h or
who had four or more migraine headaches per month should
be referred to their doctor (see Appendix; MQ for Australian
Study, Question 5). Overall, 35.8% of subjects in the Aus-
tralian study reported a duration of [24 h and 22.0%
reported at least four migraines per month headaches; 20.9
and 9.0%, respectively, thus were considered unsuitable a
non-prescription sumatriptan for these reasons alone.
In the subsequent study in Germany, the guidance was
relaxed to allow the pharmacist to recommend a triptan for
subjects whose migraine headaches lasted [24 h or who
reported four or more attacks per month, while still
advising referral to a doctor. The pharmacist suitability rate
increased to 67.5% (Table 2).
Discussion
Three studies were conducted in the UK, Australia and
Germany to validate the MQ. The study populations
reflected the typical demographic profile of migraine suf-
ferers being predominantly female and aged 30–40 [2, 9].
Pharmacists were less likely to conclude that a subject was
suitable for a triptan (48.8%) than clinicians in these
studies (76.8%). The sensitivity of the pharmacist assess-
ment of suitability was low, as expected, given that the MQ
reflects the conservative wording of the non-prescription
product information. Contraindications, warnings and pre-
cautions in the product labelling are typically strengthened
when a medicine is reclassified for non-prescription use.
Changes to the text of the MQ in the three studies may
explain why the pharmacist suitability rates ranged from
34.2 to 67.5%, while suitability rates, as determined by the
clinicians, were generally consistent (72.2–81.0%).
The false-positive rate declined progressively from 20.0
to 15.5% across the studies over time. Discordance
between the pharmacists and clinicians was primarily
related to headache diagnosis. The clinicians gave a diag-
nosis other than migraine in over half of these cases, with
Table 6 Pharmacist and clinician assessment of triptan suitability in
subjects recognised by the pharmacist to have contraindications
related to cardiovascular disease, or cardiac risk factors








Subjects with at least one
contraindication related
to cardiovascular diseaseb
No. of subjects 37 16 47
Pharmacist-assessed suitability 5.4% 0% 25.5%
2/37 0/16 12/47
Clinician-assessed suitability 62.2% 68.8% 72.3%
23/37 11/16 34/47
Subjects with at least three cardiac risk factorsc
No. of subjects 16 11 32
Pharmacist-assessed suitability 0% 0% 9.4%
0/16 0/11 3/32
Clinician-assessed suitability 56.3% 63.6% 81.3%
9/16 7/11 26/32
a Sumatriptan 50 mg for the studies in the UK and Australia; nara-
triptan 2.5 mg in Germany
b History of heart disease, stroke or transient ischaemic attack,
peripheral vascular disease/problems with circulation
c As listed in the product information for non-prescription triptans:
women who are post-menopausal; men aged over 40; high choles-
terol; parent, brother or sister developed heart disease before the age
of 60; regularly smoke more than 10 cigarettes per day; diabetic;
clearly obese
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tension-type headache being the most common. Triptans
are specific for migraine; therefore, no therapeutic benefit
would be expected in tension-type headache [10]. Potential
risks associated with triptan use in this population are
likely to be low as the pharmacist assessment also con-
siders general medical history. There were no significant
safety concerns with most of the remaining false-positive
subjects, e.g. migraine being managed well with current
OTC treatments (n = 14), vomiting during the migraine
attack (n = 8). Potential safety concerns were raised in a
few cases where a clinician reported a previous adverse
reaction to sumatriptan or naratriptan (n = 3), hypertension
(n = 2), and hemiplegic migraine (n = 2): these histories
had not been reported by the pharmacists. Hypertension,
hemiplegic migraine and hypersensitivity to sumatriptan/
naratriptan, are contraindicated for the non-prescription
products. Two subjects were classified as unsuitable for a
triptan by the clinicians because they were taking selective
serotonin reuptake inhibitors (SSRIs). Concomitant use of
SSRIs is included as a warning, not a contraindication, on
the product information for prescription and non-prescrip-
tion triptans. Co-prescription of triptans and SSRIs is
widespread but cases of serotonin syndrome are rare
[11], and it is unclear whether concomitant use increases
the risk of serotonin syndrome [12]. Despite the false-
positive cases, the MQ is considered to be of value in
guiding appropriate recommendation by pharmacists.
The Triptan Cardiovascular Safety Expert Panel con-
cluded that the safety profile of triptans is well defined and
appears to reflect a very low risk of serious cardiovascular
adverse events based on use in patients without known or
suspected coronary artery disease [13]. The pharmacists,
using the MQ, were more cautious than the clinicians in
evaluation of cardiovascular contraindications and cardiac
risk assessment (Table 6).
Post-marketing safety data are considered to provide a
reflection of overall prescribing behaviour. Since pharma-
cists were more conservative in recommending a triptan
than clinicians in these studies, non-prescription supply
would not be expected to reduce the benefit-risk balance,
assuming that the clinicians are representative of the gen-
eral population of prescribers. The UK and German
regulatory authorities reviewed all relevant safety data and
concluded that sumatriptan 50 mg and naratriptan 2.5 mg,
respectively, are suitable for non-prescription use. GSK
undertakes a regular, systematic review of the safety data.
There has been no change in the pattern of adverse event
reporting for either sumatriptan or naratriptan since they
were launched as non-prescription medicines.
The intention in our studies was for clinicians to use their
standard practice to assess patients with migraine because
this represents the benchmark against which the pharmacists
should be compared. Accordingly, the clinicians were not
provided with tools to assist in the recognition of migraine.
Not surprisingly, the clinicians did not have a consistent
approach to the diagnosis of migraine. While ‘gold standard’
diagnostic criteria have been developed [14], directing their
use would have been inappropriate in these studies.
Questions relating to migraine headache duration and
frequency in the version of the MQ tested in Australia were
unduly restrictive. The MQ guidance notes were therefore
reviewed and relaxed for the final study to allow pharma-
cists to consider a subject as potentially suitable for a
triptan if duration was [24 h or if migraine occurred at
least four times per month. There is no clinical reason to
rule out supply of a non-prescription triptan in either sit-
uation, although referral to a doctor is appropriate because
prolonged or frequent migraine attacks may be indicators
for prophylactic therapy and/or further investigation. In a
survey of adult migraine sufferers, the median duration of
the headache phase of an untreated migraine attack was
24 h, with a mean duration of 28 h (males) and 37 h
(females), and 13% reported an attack frequency of greater
than four per month [9]. The pharmacist suitability rate
increased from 34.2% in the Australian study to 67.5% in
the German study. The MQs that are being used in the UK1
and in Germany to support pharmacist recommendation of
a triptan are similar in content and structure to the version
tested in the German study.
A reduction in migraine-related disability is considered
to be one of the key benefits of making triptans available
from pharmacies [6]. The importance of consumers
receiving professional advice at the point of sale has also
been recognised [6]. Use of the MQ addresses this need by
guiding a dialogue between the pharmacist and consumer.
The MQ has been shown to be an effective tool to support
pharmacist recommendation of a non-prescription triptan.
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